Buy Pfizer - Stock

Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:

: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings.

: Trading at approximately 15x to 20x estimated earnings and significantly below its pandemic-era highs, the stock is considered undervalued by several analysts. With a market cap of roughly $153.59 billion , many argue the downside risk is cushioned by the existing pessimistic sentiment. buy pfizer stock

: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00

As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500. Potential buyers must weigh the value proposition against

AI responses may include mistakes. For financial advice, consult a professional. Learn more

The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars: With a market cap of roughly $153

: To offset the loss of exclusivity (LOE) on blockbusters like Eliquis and Ibrance, Pfizer is aggressively reinvesting in oncology and obesity. Key 2026 catalysts include the start of 20 pivotal clinical trials , notably in the high-growth GLP-1 (obesity) market and next-generation cancer therapies. Key Risks and Headwinds